<DOC>
	<DOCNO>NCT02384421</DOCNO>
	<brief_summary>Continuous deep brain stimulation ( cDBS ) establish therapy major motor sign Parkinson 's disease . Currently , cDBS limit `` open-loop '' stimulation , without real-time adjustment patient 's state activity , fluctuation type motor symptom , medication dosage , neural marker disease . The purpose study determine adaptive DBS system , respond patient specific , clinically relevant neural kinematic feedback , effective continuous DBS motor Unified Parkinson 's Disease Rating Scale ( UPDRS III ) specific phenotypic measure Parkinson 's Disease .</brief_summary>
	<brief_title>Adaptive Closed Loop Neuromodulation Neural Signatures Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . A diagnosis idiopathic Parkinson 's disease , bilateral symptom Hoehn Yahr Stage great equal II . 2 . Documented improvement motor sign versus dopaminergic medication , change Unified Parkinson 's Disease Rating Scale motor ( UPDRS III ) score &gt; = 30 % medication . 3 . The presence complication medication wear sign , fluctuate response and/or dyskinesia , and/or medication refractory tremor , and/or impairment quality life medication due factor . 4 . Subjects stable dos medication , remain unchanged DBS system activate . After DBS system optimize ( time overall medication dose may reduce avoid discomfort complication dyskinesias ) medication dose remain unchanged , possible , duration study . 5 . Treatment carbidopa/levodopa , dopamine agonist maximal tolerate dos determine movement disorder neurologist . 6 . Ability willingness return study visit , initial programming three , six twelve month DBS . 7 . Age &gt; 18 1 . Subjects significant cognitive impairment and/or dementia determine standardized neuropsychological battery . 2 . Subjects clinically active depression , define accord Diagnostic Statistical manual Mental Disorders , Fourth Edition ( DSMIV ) criterion score validated depression assessment scale . 3 . Subjects advance Parkinson 's disease , Hoehn Yahr stage 5 medication ( nonambulatory ) . 4 . Age &gt; 80 . 5 . Subjects implant electronic device neurostimulator , cardiac pacemaker/defibrillator medication pump . 6 . Subjects , pregnant , capable become pregnant , breast feeding . 7 . Patients cortical atrophy proportion age focal brain lesion could indicate nonidiopathic movement disorder determine MRI 8 . Subjects major comorbidity increase risk surgery ( prior stroke , severe hypertension , severe diabetes , need chronic anticoagulation aspirin ) . 9 . Subjects prior intracranial surgery . 10 . Subjects history seizure . 11 . Subjects , immunocompromised . 12 . Subjects active infection . 13 . Subjects , require diathermy , electroconvulsive therapy ( ECT ) , transcranial magnetic stimulation ( TMS ) treat chronic condition . 14 . Subjects , inability comply study followup visit . 15 . Subjects , unable understand sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>